Epidemiological studies have shown that an elevated uric acid (UA) level predicts the development of metabolic syndrome and diabetes; however, there is no direct evidence of this, and the underlying mechanism remains unclear. Here, we showed that a high-UA diet triggered the expression of pro-inflammatory cytokines, activated the NF-κB pathway, and increased gliosis in the hypothalamus. Intracerebroventricular injection of UA induced hypothalamic inflammation and reactive gliosis, whereas these effects were markedly ameliorated by the inhibition of NF-κB. Moreover, magnetic resonance imaging confirmed that hyperuricemia in rodents and humans was associated with gliosis in the mediobasal hypothalamus. Importantly, the rats administered UA exhibited dyslipidemia and glucose intolerance, which were probably mediated by hypothalamic inflammation and hypothalamic neuroendocrine alterations. These results suggest that UA can cause hypothalamic inflammation via NF-κB signaling. Our findings provide a potential therapeutic strategy for UA-induced metabolic disorders.
Hyperuricemia has emerged as a major health problem in industrialized nations. Epidemiological evidence has indicated that the prevalence of hyperuricemia is increasing worldwide1. It is estimated that 5–10% of adult Americans suffer from hyperuricemia2. In Asia, the prevalence of hyperuricemia is 26.1% for men and 17.0% for women3. Hyperuricemia has been thought to be part of the cluster of metabolic abnormalities that includes glucose intolerance and dyslipidemia4. Recently, elevated serum uric acid (UA) has been considered to be an independent predictor of obesity5, fatty liver, and diabetes6. Laboratory studies have shown a contributory role of UA to metabolic syndrome, which features dyslipidemia, insulin resistance, and hypertension7. Fructose-induced hyperuricemia induces insulin resistance, and lowering UA using xanthine oxidase inhibitors ameliorates the elevation of serum triglycerides and insulin resistance8. Additionally, xanthine oxidoreductase-knockout mice fail to become fat due to a defect in adipogenesis9. Despite this progress, little is known regarding the association of hyperuricemia with metabolic disorders and the underlying mechanism.
Growing evidence has suggested that immune-cell-mediated tissue inflammation acts as a key mechanism of metabolic disorders in metabolically active organs10. The hypothalamus is the “headquarters” for the regulation of energy homeostasis11, and hypothalamic inflammation is an early event in the development of metabolic abnormalities in peripheral tissue12. Hypothalamic inflammation increases baseline plasma insulin, which is accompanied by impaired insulin signaling in liver and skeletal muscle13,14. Hypothalamic dysfunction is sufficient to induce obesity and diabetes in genetic mouse models with neuronal ablation of insulin signaling15. These findings indicate that hypothalamic dysfunction plays an important role in altered energy metabolism.
UA has been shown to have pro-inflammatory activity. It induces NADP-oxidase activation by activating redox-dependent pro-inflammatory signaling in cultured adipocytes13. Additionally, UA upregulates the expression of Crp, a marker of inflammation, in human vascular smooth muscle cells and endothelial cells16. However, whether it is neuroprotective or neurotoxic in the central nervous system remains controversial17,18. Few studies have examined the relationship between UA and hypothalamic inflammation.
NF-κB is a pro-inflammatory master switch that controls the production of inflammatory markers and mediators. NF-κB activation induced by UA has been reported in several diseases. For example, UA induces renal inflammation in gouty nephropathy via the activation of tubular NF-κB signaling19. Soluble UA induces inflammatory pathways by activating p38 MAPK and NF-κB in rat vascular smooth muscle cells20. Recent studies have revealed that the pro-inflammatory NF-κB pathway mediates hypothalamic inflammation to cause metabolic syndrome12,21. It is of note that in addition to being an inflammatory regulator, IKKβ/NF-κB controls cell survival, growth, apoptosis and differentiation in a cell-specific manner22. Specific suppression of NF-κB signaling broadly across the brain, locally within the mediobasal hypothalamus, or specifically in hypothalamic AgRP neurons significantly protects against metabolic disorders12.
In the present study, we found that serum UA can pass through the blood-brain barrier (BBB) and act as a potent inflammatory stimulus, leading to NF-κB activation as well as the accumulation of gliosis in the hypothalamus, both in animal models and in humans.
Systemic hyperuricemia induces hypothalamic inflammation in rodents
To investigate the effect of UA on the hypothalamus, we applied a previously reported strategy to generate a hyperuricemia model. Rats were fed a high-UA diet (HUAD) containing 2% oxonic acid (OA) and 2% UA for 3 months23,24. OA can inhibit UA to metabolize into allantoin in rodents6. But it’s a partial inhibitor with a short half-life and rats treated with OA alone develop mild hyperuricemia, we added UA as a supplement. Serum UA concentrations in rats fed a HUAD for 28 days were increased relative to control rats fed standard chow and were approximately 3-fold higher than that in control rats at the end of 3 months (Fig. 1A), indicating that the hyperuricemic rat model was developed successfully.
Hypothalamic inflammation is an early event in the development of metabolic disorders and is evident in rodents within 1–3 days of high-fat-diet onset25. Using quantitative real-time PCR (qRT-PCR), we analyzed the transcriptional levels of inflammatory genes in the hypothalamus. We found that the gene expression profile exhibited a complex “on-off” pattern, which showed upregulation in Il1b, Tnfa, and Ikbkb mRNA within the first 7 days of HUAD administration, followed by a decline to baseline or to a slightly elevated level from days 14 to 28 (Fig. 1C,D,H). The expression levels of Il6 and Nfkbia were elevated even on the first day of the HUAD and increased by approximately 50% within 28 days (Fig. 1B,G). These results showed that HUAD could induce hypothalamic inflammatory gene expression.
In addition to the hypothalamus, we also detected the pro-inflammatory cytokines expression in the prefrontal cortex and hippocampus. The results showed that pro-inflammatory cytokines increased in the hippocampus after 3 months of HUAD administration. It has been reported that obesity-induced diabetes is associated with hippocampal chronic inflammation and is considered a risk factor for neurodegeneration26,27. We hypothesize that UA may be associated with memory impairments. However, because we aimed to investigate the effect of UA on metabolism regulation, we mainly focused on the hypothalamus in this study.
Markers of gliosis during serum UA elevation
The activation, recruitment, and proliferation of microglia and astrocytes, collectively termed “reactive gliosis”, is a hallmark of the brain’s response to neuronal injury25. The effect of UA on astroglial responses in rats was assessed by GFAP immunostaining. As expected, GFAP-positive astrocytes were scattered throughout the arcuate nucleus (ARC) of rats (Fig. 2A). Within 28 days of HUAD administration, however, the intensity of GFAP staining in the ARC increased by approximately 2-fold and remained at this high intensity over the next 2 months (Fig. 2B; quantified on the lower right), suggesting an effect of HUAD in promoting astrocyte accumulation in this brain area. Furthermore, the astrocytes became increasingly enlarged, indicative of a more active morphology. Using immunofluorescence to detect the microglia-specific cytoplasmic marker Iba-1, we found that the number of microglia clearly increased in the ARC over the duration of HUAD exposure compared to those in the chow-fed controls (Fig. 2C). Concomitantly, microglia increased in size and adopted a more activated morphology. Collectively, these results showed that the rapid onset of hypothalamic inflammation induced by a HUAD was accompanied by robust glial responses in the MBH.
UA passes through the BBB and acts as an inflammatory stimulus in the hypothalamus
To investigate whether UA could pass through the BBB and play a role on the brain, we assessed UA levels in the cerebrospinal fluid (CSF) and in hypothalamic tissue using liquid chromatography tandem mass spectrometry. We found that the average UA concentration in the CSF of HUAD-fed rats was 644.25 ng/ml, which was 1.34-fold higher than the concentrations of chow-fed control rats (Fig. 3A). The amount of UA in the hypothalamic tissue of HUAD-fed rats was 208.9 ng/g, whereas it was 87.7 ng/g in chow-fed controls (Fig. 3B). The serum UA concentrations in the HUAD and control groups were 31.86 and 9.69 μg/ml, respectively (Fig. 3C). These data indicated that UA could pass through the BBB and deposit in hypothalamic tissue. Additionally, the amount of UA in both the hypothalamus and CSF of HUAD-fed rats was significantly elevated.
To determine the direct effect of UA in inducing pro-inflammatory cytokines in the hypothalamus, rats were intracerebroventricularly (icv) cannulated and perfused continuously with UA. It has been reported that the average volume of ventricular CSF (lateral, third, and fourth ventricles) in the rat is 7–34 μl, the total cranial CSF volume is 200–440 μl, and the CSF flow rate within the ventricular system is 2.5–3.7 μl /min28,29. According to these values, the dose of UA used in this study was 3000 ng/ml, with a volume of 10 μl and a rate of 1 μl/min. As expected, 14 days of icv UA treatment produced a significant increase in the expression of pro-inflammatory cytokines in the hypothalamus (Fig. 3D–I), some of which increased as early as the first day. These results suggested that UA can act directly on the hypothalamus and induce hypothalamic inflammation.
Changes in gliosis upon UA stimulation
To detect the rapid onset of gliosis in response to UA, the gene expression of Gfap in the hypothalamus was assessed. We found that hypothalamic Gfap mRNA levels increased by 47% after UA icv perfusion for 3 days and were elevated by 96% at day 7. At day 14, a slight elevation of 59% was observed (Fig. 4C). The number of astrocytes in the ARC increased almost 3-fold (Fig. 4A; quantified in Fig. 4D); moreover, we observed through visual evaluation that the size of astrocytes became increasingly larger, indicative of a more active morphology (Fig. 4A). In addition, the effect of UA on microglia was assessed by Iba-1 immunostaining. The number of microglia increased significantly in the ARC on the first day of UA icv perfusion, remained elevated throughout the 2-week period, and increased up to 2- to 3-fold higher than the control at the end of the experiment (Fig. 4B; quantified in Fig. 4E).
NF-κB is the main link between UA and hypothalamic inflammation
To further verify that hypothalamic inflammation was induced by the pathogenic effect of UA rather than transient stimulation, C57BL/6J mice were icv cannulated and perfused with 3000 ng/ml UA or an equal dose of allantoin, a metabolite of UA in rodents. After 2 weeks of administration, the expression of hypothalamic pro-inflammatory cytokines and Nfkbia was determined. We found that UA markedly increased the mRNA levels of the pro-inflammatory cytokines and Nfkbia (Fig. 5A–D). However, allantoin did not exhibit such an effect (Fig. 5A–D). These results indicated that the pathogenic effect of UA but not transient UA stimulation may contribute to hypothalamic inflammation.
NF-κB is a critical mediator of nutritionally induced inflammation and metabolic dysfunctions30,31, we hypothesized that NF-κB may link UA to hypothalamic inflammation. To explore this hypothesis, BAY11-7085, a specific NF-κB inhibitor, was administered into the lateral ventricle 30 min before UA icv administration in C57BL/6 J mice32. Importantly, BAY11-7085 markedly inhibited the UA-induced upregulation of pro-inflammatory cytokines and Nfkbia (Fig. 5E–H), suggesting that hypothalamic NF-κB activation may be an important signaling event linking UA with hypothalamic inflammation.
UA induces NF-κB activation in neurons in vitro
Our findings described above confirmed that hypothalamic inflammation and gliosis occurred as early as the first day of the hyperuricemia model in rats. To further demonstrate the UA-mediated hypothalamic inflammation, immunostaining for NeuN, GFAP, Iba-1, and the p65/RelA subunit of NF-κB was performed in primary cultures of hypothalamic cells. We observed p65/RelA activation in neurons after exposure to 600 and 3000 ng/ml UA for 24 h (Fig. 6A), which was characterized by p65/RelA translocation to the nucleus. However, p65/RelA was barely activated in glial cells exposed to UA (Fig. 6B,C). To further study the potential role of UA in inducing inflammation, western blotting was carried out to detect the expression of pro-inflammatory cytokines in cultured SH-SY5Y human neuroblastoma cells, which naturally express insulin and leptin receptors. Consistently, TNF-α and IL-6 expression was also significantly increased in SH-SY5Y cells exposed to UA for 48 h (Fig. 6D).
Magnetic resonance imaging (MRI)-based quantitative assessment of hypothalamic gliosis in hyperuricemia rodents and humans
Gliosis is a well-characterized neural tissue response to injury from inflammatory insults33. We showed that consuming a HUAD induced inflammation associated with gliosis in the hypothalamus of rats. To histologically confirm the gliosis induced by the HUAD, MRI was used to detect gliotic changes quantitatively.
Regions of interest (ROIs) and example images from the 2-dimensional sequence, T2 parametric map, and DTI-EPI sequence are shown (Fig. 7A,B). There was a significant difference in T2 relaxation time in the hypothalamic ROIs between hyperuricemia rats and chow-fed rats, indicating that UA could significantly increase T2 relaxation times (Fig. 7C). Moreover, the effect of lengthening T2 relaxation time in the MBH persisted when the left and right MBH were analyzed separately in the model (left P < 0.01; right P < 0.05); however, laterality (right vs. left) had no effect (P = 0.13). Using diffusion tensor imaging (DTI), values were compared for fractional anisotropy and tensor trace assessments. The tensor trace showed a pattern similar to the T2 relaxation times, confirming that inflammation occurred (Fig. 7D); however, laterality (right vs. left) showed no effect (P = 0.41). Nevertheless, there was no significant difference in fractional anisotropy (Fig. 7E). These results confirmed that gliosis occurred in the hypothalamus of the hyperuricemia rats.
We then investigated whether MBH gliosis could also occur in hyperuricemia subjects. We analyzed the data obtained from 15 hyperuricemia subjects with MRI examinations and from 16 normal subjects. The concentration of serum UA in these hyperuricemia subjects ranged from 424 to 659 μM for men and from 397 to 518 μM for women, whereas the average concentration was 293.1 μM in normal subjects. We performed an initial inspection of the MBH for hyperintense signal in T2 coronal sections, as performed in the rodent study described above. Hyperintense signal in the MBH is a characteristic finding of gliosis in numerous inflammatory, ischemic, and degenerative neural disorders in clinical34. To detect gliotic changes below the visual detection threshold and to eliminate the influence of changes in background between different batches of imaging, ratios were created to compare the mean signal intensity between ROIs placed in the MBH and ROIs in adjacent amygdala tissue. ROIs are shown by white circles and arrows in the representative images from a normal subject and a hyperuricemia subject (Fig. 7F,G). Very importantly, in group comparisons, the right and left MBH/amygdala mean signal intensity was significantly higher among hyperuricemia subjects (1.083 ± 0.019) than that in normal UA subjects (0.988 ± 0.016) (Fig. 7H). Collectively, our retrospective analysis suggested that hyperuricemia in humans is very likely associated with gliosis in the MBH (Fig. 7I), which is a well-characterized neural tissue response to inflammatory insults33.
UA leads to dyslipidemia and glucose intolerance
The hypothalamus is the nerve center responsible for metabolism. To track UA in relation to lipid and glucose metabolism, we measured several biochemical parameters in serum collected from the HUAD-fed rats (Fig. 8A–C) and UA icv-injected rats (Fig. 8D–F). Interestingly, the rats treated with these two UA administration approaches showed dyslipidemia. The blood pressure of the rats subjected to 3 months of a HUAD was somewhat increased (Fig. 8G). We then performed an oral glucose tolerance test (OGTT) and a fasting serum insulin detection test at various time points7,35. We found that HUAD-fed rats exhibited a significantly higher blood glucose concentration (Fig. 8H,I) as well as an increased level of serum insulin (Fig. 8J) than chow-fed control rats. The same was true for UA icv-injected rats. In the OGTT, the glucose area under the curve (AUC) showed an 8% and 12% increase in the rats receiving icv UA perfusion for 1 and 2 weeks, respectively (Fig. 8K,L).
Moreover, glucose intolerance also occurred in the mice receiving icv UA perfusion, raising the possibility of a common phenomenon of UA-induced glucose metabolic disorders across species (Fig. 8M). Importantly, the inhibition of NF-κB by icv injection of BAY11-7085 protected mice against UA-induced glucose intolerance (Fig. 8N); moreover, the glucose AUC in the OGTT almost recovered to normal (Fig. 8O). The UA-induced elevation of CHOL, LDL, and HDL was also ameliorated by NF-κB inhibition (Fig. 8P–R). These results suggested that NF-κB plays an important role in UA-induced metabolic disorders.
To investigate the events linking UA-induced hypothalamic inflammation to metabolic disorders, we measured mRNA levels of the relevant hypothalamic neuroendocrine factors involved in the control of feeding, glucose levels and thermogenesis36. Importantly, we found an “on-off” pattern in the gene expression; mRNA levels of Agrp, Pomc, Crh, Trh, Ghrh, and Gnrh were elevated in the hypothalamus within the first 7 days of HUAD administration, followed by a decline to almost 50% of the control levels from days 14 to 28 (Supplementary Fig. S1A,B). And two of the neuroendocrine factors, Crh and Trh, which are important for thermogenic function, decreased in the rats with icv UA administration (Supplementary Fig. S1C). Because the transcriptional integration of NF-κB, c-Jun and PKC pathways seems to account for the downregulation of hypothalamic neuroendocrine factors, we then assessed the mRNA levels of the c-fos, c-jun, Prkca, Prkcd, and Prkcq genes in the hypothalamus of rats that received a HUAD for 14 and 28 days (Supplementary Fig. S1D) or that received icv UA perfusion for 14 days (Supplementary Fig. S1E). Interestingly, we found that Prkcd, the gene that encodes PKC-δ, changed significantly, suggesting that UA activates hypothalamic NF-κB signaling and causes neuroendocrine disorders at least partially through PKC-δ, eventually leading to systemic metabolic disorders.
In the present study, pro-inflammatory cytokine gene expression displayed a “on-off” pattern in response to UA, and an increase in pro-inflammatory cytokines and gliosis in the hypothalamus occurred during the early phase of UA stimulation. We thus hypothesize that the rapid onset of MBH inflammation could be a manifestation of neuronal injury that then triggers reactive gliosis involving microglial and astroglial cell populations, both of which are thought to limit the extent of inflammation and neuron loss in brain injury37. The transient response of glial cells to UA suggests that neuroprotective responses could be mounted to limit or reverse the injury during its initial phases and cause the expression of pro-inflammatory markers to return to basal levels in the MBH. However, with sustained exposure to UA, the capacity of supportive glial cells to control the damage is exceeded, such that chronic inflammation and reactive gliosis are generated in the hypothalamus. Our findings in primary hypothalamic neural cells also showed that NF-κB was activated in neurons but not in glial cells after UA exposure. Therefore, it is reasonable to conjecture that glial cells play an important neuroprotective role under conditions in which the initial UA-induced insult is likely directed at neurons rather than glial cells. Our findings are supported by similar observations in demyelinating or neurodegenerative disease38,39.
Several mechanisms have been reported to explain overnutrition-induced inflammation, including the activation of TLR4, serine/threonine kinases and endoplasmic reticulum stress40. In the present study, the gene expression of Ikbkb, Ikbke, and Nfkbia increased significantly after UA stimulation, suggesting that UA-induced inflammation may be mediated by the activation of the IKK/NF-κB pathway. In fact, previous studies have demonstrated that IKKβ/NF-κB activation in hypothalamic neurons is a general cause of metabolic abnormalities due to overnutrition41. Conversely, ablation of IKKβ in hypothalamic AgRP and POMC neurons significantly protects against glucose intolerance12. In fact, in addition to its role as an inflammatory regulator, NF-κB signaling also controls cell survival, apoptosis and synaptic plasticity42. For example, p65 regulates the proliferation of adult neural stem cells through the NF-κB target genes c-myc and cyclin D143,44. In the mature nervous system, NF-κB is activated in synapses in response to excitatory synaptic transmission and may play a pivotal role in processes such as learning and memory45.
Whether IKK/NF-κB signaling is activated in glial cells in conditions of overnutrition has been heavily debated until now. Some studies have shown that the hypothalamic dysregulation induced by overnutrition involves a neuron-specific program through IKKβ/NF-κB and that inflammatory cytokines do not have strong effects in non-neuronal cells31. However, others have shown that in conditions of chronic inflammation induced by overnutrition and senescence, NF-κB is activated in microglia, which are regarded as the macrophage-like immune cells of the brain. Moreover, pro-inflammatory cytokines, such as TNF-α and IL-6, released from microglia work on appetite-controlling neurons to further activate NF-κB27. In the primary hypothalamic culture experiments performed in the present study, NF-κB was mainly activated in neurons in response to UA and not in glial cells, suggesting that a neuron-specific program involving IKK/NF-κB signaling pathway plays a role.
In recent years, multiparametric high-field MRI approaches have been used to assess and quantify gliosis in the MBH, based on the techniques of T2 relaxation time or DTI34. In particular, T2 relaxation time is significantly correlated with histopathological gliosis and is considered a promising quantitative radiological marker of gliosis in the MBH, despite its minute size33,34. In our study, T2 relaxation times were significantly different in the gliotic MBH of HUAD-fed rats, which was characterized by an increased density of both astrocytes and microglia. We extended the finding of the high MBH T2 signal by associating it with high serum UA levels in humans. Importantly, through a retrospective analysis of T2 MRI obtained in a cohort of human subjects undergoing clinical examination, we found that the intensity of the T2 signal (hyperintensity is an indicator of gliosis) was significantly increased in the human MBH in individuals with hyperuricemia. This finding does not constitute definitive proof of increased gliosis because edema, infection, and tumors could have a similar appearance. However, subjects with preexisting evidence of neurological abnormalities were excluded from the study, and these alternative explanations for increased T2 signal intensity are unlikely. Because MRI is a safe and established tool for human brain imaging, our study suggests that MRI-based techniques have translational value because they can be used to make comparable measurements of gliosis in the MBH of humans. MRI may be a potential technique for the prediction of metabolic diseases because hypothalamic gliosis is an early event that precedes dysfunction in peripheral tissues.
We found that rats exhibited dyslipidemia and glucose intolerance during UA stimulation and that the inhibition of hypothalamic inflammation by an NF-κB inhibitor remarkably ameliorated glucose intolerance. This evidence suggests that the inflammation induced by UA in the hypothalamus could be one of the potential causes of metabolic disorders. This notion is supported by previous studies that evaluated the isolated effect of low-grade hypothalamic inflammation on peripheral insulin action. Lean rats with icv administration of a low dose of TNF-α exhibit impairment of leptin’s anorexigenic effects, hyperglycemia, and impairment of insulin signal transduction in liver and muscle14,46. Additionally, icv injection of saturated fatty acids induces an increase in TNF-α expression and inflammatory signal transduction through the activation of TLR4 and PKCτ in the hypothalamus47,48. In fact, a growing number of studies has indicated that the key mechanisms of dyslipidemia and glucose intolerance may originate in the brain, especially in the hypothalamus, because multiple hypothalamic changes occur prior to substantial diabetes and obesity25,49. Therefore, we speculate that some nutrients in the diet or abnormal levels of endogenous substances, such as UA in our study, may stimulate the hypothalamus to produce inflammation directly, leading to the changes in various peripheral tissues.
In summary, the consumption of a HUAD induces hypothalamic inflammation and reactive gliosis in both rodents and humans. Experimental and clinical data indicate that hypothalamic inflammation mediated by NF-κB signaling may be implicated in the pathogenesis of metabolic disorders induced by UA. However, there is a limitation in our study. In the retrospective study in humans, we only compared mediobasal hypothalamus MRI signal intensity of hyperuricemia group and the normal group. But due to time constraints, we did not track the prognosis of these subjects, which is likely to further illustrate the viewpoint of this study.
Preparation of reagents
UA used in icv administration in vivo or in cell culture was prepared as follows: UA was dissolved in saline, sonicated for 30 min, and filtered with a 0.22 μm membrane filter, followed by observation under a microscope to confirm the absence of UA crystals.
Weight-matched male Wistar rats (300–350 g) and male C57BL/6J mice (7–8 weeks old) were purchased from Beijing Animal Center (Beijing, China). All of the animals were housed individually in a specific pathogen-free environment, maintained in a temperature-controlled room with a 12-hour-light/12-hour-dark cycle, and provided with ad libitum access to water.
To establish the hyperuricemia model, the rats were provided with a HUAD containing 2% OA and 2% UA for periods ranging from 1 day to 3 months23,24. The animals were anaesthetized with sodium pentobarbital before necropsy. All of the animal protocols were reviewed and approved by the Experimental Animal Ethics Committee of Sichuan University (Chengdu, China)50,51, and the methods were carried out in accordance with the approved guidelines.
Icv cannulation and icv administration
Wistar rats and C57BL/6J mice were placed in a stereotaxic apparatus (Ruiwode, Shenzhen, China) according to a previously described method52. A stainless steel guide cannula was stereotaxically implanted into the lateral cerebral ventricle of the rats (1.5 mm lateral and 0.8 mm posterior to bregma, 4.0 mm ventral to the surface of the skull). After cannulation, the rats were treated with ampicillin sodium (0.2 g/ml, 600 μl/kg, intramuscular, twice daily) for 4 days. After a 3-day recovery period, the icv-cannulated rats were treated daily with 10 μl UA (3000 ng/ml, 1 μl/min) for 1, 3, 7 or 14 days.
The coordinates (relative to bregma) for icv cannula implantation in mice were 1.0 mm lateral, -0.42 mm anteroposterior, and 2.2 mm deep53. After cannulation, the mice were treated the same as the rats (described above). After 4 days of antimicrobial therapy and 3 days of recovery, the icv-cannulated animals were administered 2 μl normal saline, UA (600 ng/ml and 3000 ng/ml) or allantoin (3000 ng/ml) daily for 14 days. To inhibit NF-κB activation in the hypothalamus, 2 μl BAY11-7085 (500 nmol) was icv injected 30 min before the injection of UA32. The infusion rate for normal saline, UA, allantoin, and BAY11-7085 was approximately 1 μl/min.
Retrospective study of brain MRI in humans
We performed a retrospective cohort study to search for radiological evidence of MBH gliosis and to correlate our findings with hyperuricemia. Magnetic resonance brain examinations that used pituitary or epilepsy imaging protocols with coronal T2 FES FLAIR sequences and that were performed between 3/1/2014 and 6/20/2014 at West China Hospital of Sichuan University were reviewed for 2 inclusion criteria: the availability of high quality coronal views of the hypothalamus and the absence of clinical abnormalities that might confound interpretation (e.g., hypothalamic-pituitary axis disease). For the 51 subjects that met our inclusion criteria, we reviewed electronic medical records to determine serum UA concentration, gender, age, body weight, and final diagnosis. Exclusion criteria were as follows: absence of serum biochemical analysis for UA; age of less than 16 or more than 70 years; diagnosis of pituitary, hypothalamic, or neurodegenerative disorder (e.g., multiple sclerosis); metabolic disease (hyperglycemia, hyperlipemia, fatty liver, hyperinsulinemia, diabetes, and obesity); serum biochemical parameter abnormalities without definite metabolic disease (including CHOL, TG, HDL, LDL, and GLU); cerebral atrophy; and history of bariatric disease. Twenty subjects were excluded (age <16 [n = 2]; age >70 [n = 1]; metabolic disease [n = 5]; serum biochemical parameter abnormalities [n = 9]; CNS disease [n = 3]), yielding a total of 31 study participants. All subjects were classified into 2 groups: the hyperuricemia group (fasting serum UA >416 μM for men, >357 μM for women) and the normal group. The basal characteristics of the study population are provided in Supplementary Table S1. ROIs in the bilateral MBH and amygdala were defined by a neuroradiologist, who was blinded to all clinical information. Mean ROI signal intensity, standard deviation, and ROI area were measured using proprietary software on the PACS workstation (Centricity, GE Healthcare). Ratios were calculated by comparing the mean signal intensity in the MBH on each side with that in the ipsilateral amygdala ROI. Our study was approved by the Medical Ethics Committee (Human) of West China Hospital and Sichuan University. All subjects had been informed and approved participation in this study, and “informed consent” was obtained from all subjects. The methods were carried out in accordance with the approved guidelines.
Data are presented as the mean ± SEM. Differences between two means were assessed by unpaired, two-tailed Student’s t test. Data involving more than two means were evaluated by one-way ANOVA followed by Tukey’s post-hoc tests (SigmaStat [SyStat] and GraphPad Prism [GraphPad Software, Inc.]). P values less than 0.05 were considered statistically significant.
How to cite this article: Lu, W. et al. Uric Acid Produces an Inflammatory Response through Activation of NF-κB in the Hypothalamus: Implications for the Pathogenesis of Metabolic Disorders. Sci. Rep. 5, 12144; doi: 10.1038/srep12144 (2015).
This work was supported by National Science & Technology Major Project (2012ZX09302-004), National Natural Sciences Foundation of China (81271467, 81272459, 30970938, and 81322035).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/